title: Effect of thyroid hormones on pituitary neuromedin B and possible interaction between thyroid hormones and neuromedin B on thyrotropin secretion.
abstract: Neuromedin B (NB), a bombesin-like peptide, has been recently characterized as a physiological paracrine/autocrine inhibitor of thyrotropin (TSH) secretion. We hypothesized on the basis of our prior experiments that thyroid hormones stimulate pituitary NB secretion which mediates, at least in part, the TSH-suppressive effect of thyroid hormone. Here, we evaluated the time-course of the effect of thyroid hormones administration to eu- and hypothyroid rats on the anterior pituitary content of NB and on serum TSH. As previously reported, the pituitary content of NB increased in hyperthyroidism and decreased in hypothyroidism. Chronic treatment of hypothyroid rats with a physiological dose of thyroxine (0.8 microgram/100 g b.w. s.c, for 3 or 5 days) normalized pituitary NB content, while 5 days of treatment with a pharmacological dose of thriiodothyronine (0.4 microgram/100 g b.w.) induced an increase above that of normal pituitaries. Thyroxine and triiodothyronine injected once, s.c., into hypothyroid rats required 30 min to normalize NB content, which reached higher than normal values in 3-6 h. At these times, the increment in NB preceded or was simultaneous with the suppression of serum TSH. This rapid and marked effect on pituitary neuromedin B content, associated in time with TSH suppression, is in agreement with the hypothesis that neuromedin B may mediate at least in part, the acute suppression of TSH release by thyroid hormone, a hypothesis that still needs further verification.
authors.affiliation: Laboratório de Fisiologia Endócrina, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Brasil.
authors.forename: T M
authors.initials: TM
authors.lastname: Ortiga-Carvalho
authors.forename: J
authors.initials: J
authors.lastname: Polak
authors.forename: S
authors.initials: S
authors.lastname: McCann
authors.forename: C C
authors.initials: CC
authors.lastname: Pazos-Moura
mesh_terms: D000818:Animals; D013956:Antithyroid Agents / Q000494:pharmacology; D006980:Hyperthyroidism / Q000378:metabolism; D007037:Hypothyroidism / Q000378:metabolism; D008297:Male; D008713:Methimazole / Q000494:pharmacology; D015287:Neurokinin B / Q000031:analogs & derivatives* / Q000378:metabolism; D010902:Pituitary Gland / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D013963:Thyroid Hormones / Q000494:pharmacology*; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism*; D013974:Thyroxine / Q000097:blood / Q000378:metabolism / Q000494:pharmacology; D014284:Triiodothyronine / Q000097:blood / Q000378:metabolism / Q000494:pharmacology
chemical_list: D013956:Antithyroid Agents; D013963:Thyroid Hormones; D014284:Triiodothyronine; D008713:Methimazole; D015287:Neurokinin B; C038393:neuromedin B; D013972:Thyrotropin; D013974:Thyroxine